Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Neuroscience medtech firm Jialiang raises series D from Ningbo state capital, Kuanqiao ...

7 September 2026 · By · Wire by Fusion42

Published

7 September 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

China

◆ Source

Read at app.dealroom.co →

◆ Verified

Fusion42 · 7 September 2026 · Fusion42 review

Jialiang Neuroscience, a Chinese medtech company focused on brain science and neurosurgical technologies, has secured Series D funding led by Ningbo state capital and other investors to advance its brain-machine regulation and medical laser platforms.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

State capital from Ningbo has activated fresh capital flows into neurotech innovation in China. If you work on neurological devices, expect heavier competing investment and stronger regional market support.

◆ Coverage

1 source · 7 Sep 2026

◆ Related on Wire

◆ Topics

Medtechseries-dstate-capitalmedtechbrain-sciencechinese-market